Literature DB >> 15539084

Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.

Evren Alici1, Kyriakos V Konstantinidis, Alar Aints, M Sirac Dilber, Manuchehr Abedi-Valugerdi.   

Abstract

OBJECTIVE: Lack of good models for in vivo detection of multiple myeloma (MM) cells hampers our understanding of the disease. Our objective was to establish a murine model for MM, allowing sensitive and labor-free tracing and quantification of MM cells in an immunocompetent host.
METHODS: 5T33MM cells were retrovirally transduced, expressing enhanced green fluorescent protein (eGFP) and/or herpes simplex virus thymidine kinase (HSV-tk) as a control. Flow cytometric eGFP detection accuracy and sensitivity were assessed. Functional characteristics of transduced cells, including growth rate and production of IgG2b paraprotein and interleukin-6, were compared to those of nontransduced cells in vitro. For induction of MM, C57BL/KaLwRij mice were injected intravenously with transduced and nontransduced cells. Survival kinetics and distribution of eGFP cells in tissues were evaluated.
RESULTS: Flow cytometric eGFP detection was accurate at 1:1000 transduced/nontransduced cell ratio. Transduced and nontransduced 5T33MM cells exhibited similar growth rates, producing comparable IgG2b and interleukin-6 levels. Intravenous injection of both nontransduced and eGFP-transduced MM cells to C57BL/KaLwRij mice resulted in paraplegia. At the time of paraplegia, eGFP-transduced MM cells were detected substantially in the bone marrow, spleen, and liver, less in lymph nodes, but not in the thymus. The bone marrow of paraplegic mice contained higher eGFP-transduced MM cells compared to that of nonparaplegic animals.
CONCLUSIONS: In the established eGFP-5T33 MM model, MM cells are easily traced in an immunocompetent host. This model simplifies the analysis of homing pattern studies, the evaluation of therapeutic effects of various treatment approaches and contributes towards better understanding of MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539084     DOI: 10.1016/j.exphem.2004.07.019

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  13 in total

1.  Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Authors:  A Barber; K R Meehan; C L Sentman
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

2.  3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?

Authors:  Pilar de la Puente; Abdel Kareem Azab
Journal:  Future Oncol       Date:  2016-03-30       Impact factor: 3.404

Review 3.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

4.  Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.

Authors:  Sungyoul Hong; Jianfei Qian; Jing Yang; Haiyan Li; Larry W Kwak; Qing Yi
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

5.  Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.

Authors:  Chen Hao Lo; Gemma Shay; Jeremy J McGuire; Tao Li; Kenneth H Shain; Jun Yong Choi; Rita Fuerst; William R Roush; Anna M Knapinska; Gregg B Fields; Conor C Lynch
Journal:  Cancer Res       Date:  2021-02-01       Impact factor: 12.701

6.  Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms.

Authors:  He Wang; Shu Yang; Hong Zhou; Mingna Sun; Lingran Du; Minyan Wei; Meixia Luo; Jingzhu Huang; Hongzhu Deng; Yinghong Feng; Jun Huang; Yi Zhou
Journal:  J Hematol Oncol       Date:  2015-03-15       Impact factor: 17.388

7.  [(89)Zr]oxinate4 for long-term in vivo cell tracking by positron emission tomography.

Authors:  Putthiporn Charoenphun; Levente K Meszaros; Krisanat Chuamsaamarkkee; Ehsan Sharif-Paghaleh; James R Ballinger; Trevor J Ferris; Michael J Went; Gregory E D Mullen; Philip J Blower
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-31       Impact factor: 9.236

8.  Bone marker gene expression in calvarial bones: different bone microenvironments.

Authors:  Osama Al-Amer
Journal:  J Biol Res (Thessalon)       Date:  2017-05-16       Impact factor: 1.889

9.  Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma.

Authors:  Mengjie Guo; Dongdong Sun; Zhimin Fan; Yuxia Yuan; Miaomiao Shao; Jianhao Hou; Yuqi Zhu; Rongfang Wei; Yan Zhu; Jinjun Qian; Fei Li; Ye Yang; Chunyan Gu
Journal:  Front Oncol       Date:  2019-08-08       Impact factor: 6.244

Review 10.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.